Clinical trial

Dementia
#Alzheimer's #Clinical trial #Neuroscience #UK Dementia Research Institute

New UK trial could halve the time to test Alzheimer’s drugs

A first-of-its-kind clinical trial has launched in the UK, which could cut years from the search for treatments that work for people with Alzheimer’s disease.  The national trial, called AD-SMART (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial), is led by the UK Dementia Research Institute (UK DRI)… Read More

#Editor's Choice #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Clinical trial #HaemaLogiX #Oncology

KOALA trial launched to assess CAR-T for myeloma

The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.  The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More

#Cancer Research #News

Cytokine release syndrome
#Clinical trial #Cytokine Release Syndrome (CRS) #Immunotherapy #Myeloma #Oncology

New drug could improve access to immunotherapies

A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.  The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More

#Cancer Research #News

#Clinical trial #R&D

Why the biggest gains in clinical R&D won’t come from technology

Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology.  Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI-driven automation, each wave brings genuine capability and promise. Yet foundational problems like complex… Read More

#Exclusive Content #Opinion

Heart
#Clinical trial #Drug discovery #Heart disease #The University of Manchester

New drug could treat common heart disease, study shows 

A new drug that reduces heart muscle thickening could represent a new treatment option for heart disease patients, a study says.  The TEMPEST trial, led by researchers at the University of Manchester, tested the drug trientine in 154 adults with hypertrophic cardiomyopathy in a year-long, placebo-controlled study. Read More

#News

#Cancer drug targets #Clinical trial #DNA #Kairos Pharma #Prostate cancer #Stem cells #Tumour biology

Cancer drug resistance isn’t one problem, it’s many

Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it.  Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes durable clinical success. That problem is drug resistance. Therapies that… Read More

#Cancer Research #Exclusive Content

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

Magic mushrooms
#Clinical trial #Drug discovery #Psilocybin #Weight loss

‘Magic mushroom’ compounds could help treat anorexia

Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says.  A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for… Read More

#News

#Clinical trial #GLP-1 #Obesity #Weight loss

What’s the outlook for GLP-1 therapeutics?

Is the honeymoon period over for GLP-1s or is the market yet to reach its full potential? Diana Turner asks what will differentiate the next generation of these peptide analogues.  Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which is also a GIP (glucose-dependent insulinotropic polypeptide) receptor, have… Read More

#Exclusive Content

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford

DDW Highlights: 7 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More

#Podcasts

Dollar sign on a tablet
#Clinical trial #Drug development #Drug discovery #Investment

The changing landscape for drug discovery investment

As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug developers and investors looking to bring a new drug to market.  It’s no news that the discovery and development of a new drug is not only costly and lengthy - over $1… Read More

#Business & Investment #Exclusive Content

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

#News

#Biobanking #Clinical trial

Biobanking for clinical trials: Beyond storage

This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 3, Summer 2026. ​​​​Biological samples are critical across the clinical trial lifecycle, providing the raw material for understanding disease mechanisms, tracking biomarker dynamics, and evaluating both short and long‑term clinical outcomes.​​ Biobanking supports this lifecycle at every stage by providing secure sample collection, storage,… Read More

#Exclusive Content

#AI #Clinical development #Clinical trial #Norstella #Real world data

How AI has revolutionised clinical development

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Suzanne Caruso, President of Strategic Intelligence and Clinical & Regulatory at Norstella. Norstella supports drug developers looking to take their treatments from pipeline to patients, finding solutions to complexities… Read More

#Featured Podcasts #Podcasts

Diabetic eye disease
#Clinical trial #Eye health #FDA

FDA approves thyroid eye disease treatment 

The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease (TED).  TED is a rare, debilitating autoimmune disease characterised by inflammation and tissue remodelling around and behind the eyes, which can lead to proptosis, diplopia, pain and vision impairment.  Lumvoa was approved… Read More

#News #Regulatory